Clinuvel Pharmaceuticals ^Company

Clinuvel Pharmaceuticals is a biopharmaceutical company that develops drugs for severe skin disorders related to exposure to harmful UV radiation. Its lead compound, SCENESSE, prevents phototoxicity in adult patients with erythropoietic protoporphyria (EPP) by increasing melanin levels in the skin and shielding against UV radiation. SCENESSE has completed Phase II and III trials in the US and Europe and has been granted marketing authorization by the European Commission. The company operates in Europe, the US, and Singapore, and SCENESSE is delivered via a subcutaneous dissolving implant.